BlackRock Health Sciences Opportunities Portfolio Investor C Shares (SHSCX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
46.88
-0.83 (-1.74%)
May 15, 2025, 8:09 AM EDT
SHSCX Holdings List
As of Mar 31, 2025
No. | Symbol | Name | % Weight |
---|---|---|---|
1 | LLY | Eli Lilly and Company | 8.03% |
2 | ABBV | AbbVie Inc. | 6.91% |
3 | BSX | Boston Scientific Corporation | 5.43% |
4 | UNH | UnitedHealth Group Incorporated | 5.25% |
5 | ABT | Abbott Laboratories | 4.78% |
6 | TMO | Thermo Fisher Scientific Inc. | 3.55% |
7 | SYK | Stryker Corporation | 3.49% |
8 | JNJ | Johnson & Johnson | 3.01% |
9 | AMGN | Amgen Inc. | 2.99% |
10 | GILD | Gilead Sciences, Inc. | 2.98% |
11 | ISRG | Intuitive Surgical, Inc. | 2.85% |
12 | VRTX | Vertex Pharmaceuticals Incorporated | 2.52% |
13 | DHR | Danaher Corporation | 2.40% |
14 | ELV | Elevance Health, Inc. | 2.15% |
15 | MDT | Medtronic plc | 2.12% |
16 | COR | Cencora, Inc. | 2.00% |
17 | BMY | Bristol-Myers Squibb Company | 1.94% |
18 | BDX | Becton, Dickinson and Company | 1.86% |
19 | MCK | McKesson Corporation | 1.83% |
20 | EW | Edwards Lifesciences Corporation | 1.77% |
21 | ARGX | argenx SE | 1.75% |
22 | TSTXX | BlackRock Liquidity Funds - T-Fund | 1.51% |
23 | WAT | Waters Corporation | 1.39% |
24 | MRK | Merck & Co., Inc. | 1.38% |
25 | ALNY | Alnylam Pharmaceuticals, Inc. | 1.35% |
26 | REGN | Regeneron Pharmaceuticals, Inc. | 1.28% |
27 | PFE | Pfizer Inc. | 1.03% |
28 | CI | The Cigna Group | 1.02% |
29 | GEHC | GE HealthCare Technologies Inc. | 1.00% |
30 | ZTS | Zoetis Inc. | 0.97% |
31 | EPA: SAN | Sanofi | 0.94% |
32 | HUM | Humana Inc. | 0.90% |
33 | SWX: ROG | Roche Holding AG | 0.85% |
34 | INSM | Insmed Incorporated | 0.70% |
35 | LON: AZN | AstraZeneca PLC | 0.66% |
36 | TEVA | Teva Pharmaceutical Industries Limited | 0.65% |
37 | PEN | Penumbra, Inc. | 0.60% |
38 | SWX: ALC | Alcon Inc. | 0.59% |
39 | RYTM | Rhythm Pharmaceuticals, Inc. | 0.51% |
40 | IDXX | IDEXX Laboratories, Inc. | 0.51% |
41 | BIIB | Biogen Inc. | 0.48% |
42 | NBIX | Neurocrine Biosciences, Inc. | 0.47% |
43 | BPMC | Blueprint Medicines Corporation | 0.43% |
44 | WST | West Pharmaceutical Services, Inc. | 0.42% |
45 | STE | STERIS plc | 0.40% |
46 | HCA | HCA Healthcare, Inc. | 0.39% |
47 | COO | The Cooper Companies, Inc. | 0.38% |
48 | DGX | Quest Diagnostics Incorporated | 0.37% |
49 | NUVL | Nuvalent, Inc. | 0.36% |
50 | DXCM | DexCom, Inc. | 0.34% |
51 | A | Agilent Technologies, Inc. | 0.33% |
52 | NTRA | Natera, Inc. | 0.30% |
53 | RGEN | Repligen Corporation | 0.30% |
54 | LH | Labcorp Holdings Inc. | 0.29% |
55 | BMRN | BioMarin Pharmaceutical Inc. | 0.28% |
56 | EBR: UCB | UCB SA | 0.27% |
57 | ASND | Ascendis Pharma A/S | 0.27% |
58 | GKOS | Glaukos Corporation | 0.26% |
59 | TYO: 4568 | Daiichi Sankyo Company, Limited | 0.26% |
60 | MTD | Mettler-Toledo International Inc. | 0.26% |
61 | EXAS | Exact Sciences Corporation | 0.25% |
62 | ALGN | Align Technology, Inc. | 0.24% |
63 | MRUS | Merus N.V. | 0.23% |
64 | XENE | Xenon Pharmaceuticals Inc. | 0.22% |
65 | IQV | IQVIA Holdings Inc. | 0.22% |
66 | PTCT | PTC Therapeutics, Inc. | 0.20% |
67 | GH | Guardant Health, Inc. | 0.19% |
68 | ACLX | Arcellx, Inc. | 0.19% |
69 | TECH | Bio-Techne Corporation | 0.18% |
70 | PTGX | Protagonist Therapeutics, Inc. | 0.18% |
71 | MRNA | Moderna, Inc. | 0.16% |
72 | NVCR | NovoCure Limited | 0.16% |
73 | INCY | Incyte Corporation | 0.14% |
74 | HOLX | Hologic, Inc. | 0.14% |
75 | HLXB | Helix Acquisition Corp. II | 0.13% |
76 | INSP | Inspire Medical Systems, Inc. | 0.13% |
77 | BNTX | BioNTech SE | 0.13% |
78 | n/a | PROJECT LRN SERIES B Prvt | 0.12% |
79 | BBIO | BridgeBio Pharma, Inc. | 0.11% |
80 | ROIV | Roivant Sciences Ltd. | 0.11% |
81 | SRRK | Scholar Rock Holding Corporation | 0.11% |
82 | NRIX | Nurix Therapeutics, Inc. | 0.10% |
83 | n/a | Kartos Therapeutics Series C Prvt | 0.10% |
84 | RNA | Avidity Biosciences, Inc. | 0.10% |
85 | CPH: ZEAL | Zealand Pharma A/S | 0.10% |
86 | n/a | PROJECT QAT - SERIES D Prvt | 0.09% |
87 | DNLI | Denali Therapeutics Inc. | 0.09% |
88 | STOK | Stoke Therapeutics, Inc. | 0.09% |
89 | n/a | Adarx Pharmaceuticals Series C Prvt | 0.08% |
90 | ALKS | Alkermes plc | 0.08% |
91 | IONS | Ionis Pharmaceuticals, Inc. | 0.08% |
92 | BHVN | Biohaven Ltd. | 0.08% |
93 | n/a | PROJECT TARGET SERIES C Prvt | 0.08% |
94 | n/a | Genesis Therapeutics Series B Prvt | 0.07% |
95 | IRON | Disc Medicine, Inc. | 0.07% |
96 | LEGN | Legend Biotech Corporation | 0.07% |
97 | MTSR | Metsera, Inc. | 0.06% |
98 | PCVX | Vaxcyte, Inc. | 0.05% |
99 | BEAM | Beam Therapeutics Inc. | 0.05% |
100 | n/a | Icash | 0.05% |
101 | n/a | USD - OTHER PAYABLES/RECEIVABLES | 0.05% |
102 | DYN | Dyne Therapeutics, Inc. | 0.05% |
103 | GPCR | Structure Therapeutics Inc. | 0.05% |
104 | MLTX | MoonLake Immunotherapeutics | 0.04% |
105 | VKTX | Viking Therapeutics, Inc. | 0.04% |
106 | EBR: NYXH | Nyxoah SA | 0.04% |
107 | EWTX | Edgewise Therapeutics, Inc. | 0.04% |
108 | NGNE | Neurogene Inc. | 0.04% |
109 | n/a | Helix Acq Corp Pipe Commitment Prvt | 0.03% |
110 | ALLO | Allogene Therapeutics, Inc. | 0.03% |
111 | WVE | Wave Life Sciences Ltd. | 0.03% |
112 | n/a | Kartos Therapeutics Series D Prvt | 0.03% |
113 | n/a | PROJECT CLA COMMON Prvt | 0.03% |
114 | RGNX | REGENXBIO Inc. | 0.02% |
115 | VIR | Vir Biotechnology, Inc. | 0.02% |
116 | CGON | CG Oncology, Inc. | 0.02% |
117 | VYGR | Voyager Therapeutics, Inc. | 0.02% |
118 | n/a | PROJECT K SERIES B Prvt | 0.02% |
119 | AUTL | Autolus Therapeutics plc | 0.02% |
120 | n/a | CHF - Spendable Cash | 0.02% |
121 | IMTX | Immatics N.V. | 0.02% |
122 | n/a | Affinivax Milestone Placeholder Prvt | 0.02% |
123 | OBIO | Orchestra BioMed Holdings, Inc. | 0.01% |
124 | SGMT | Sagimet Biosciences Inc. | 0.01% |
125 | TCRX | TScan Therapeutics, Inc. | 0.01% |
126 | n/a | Exo Conv Bridge Note Prvt | 0.01% |
127 | ACIU | AC Immune SA | 0.01% |
128 | n/a | Abiomed Cvrs | 0.01% |
129 | FDMT | 4D Molecular Therapeutics, Inc. | 0.01% |
130 | n/a | Carbon Health Convertible Note Prvt | 0.00% |
131 | n/a | Mirati Therapeutics Inc | 0.00% |
132 | n/a | JPY - Other Payables/Receivables | 0.00% |
133 | n/a | PROJECT CRO SERIES D2 Prvt | 0.00% |
134 | n/a | USD CASH(Corp Act) | 0.00% |
135 | NUVB.WS | Nuvation Bio ([Wts/Rts]) | 0.00% |
136 | n/a | Exo Series C Pref Eq Prvt | 0.00% |
137 | n/a | PROJECT IBA COMMON Prvt | 0.00% |
138 | n/a | Afferent Contingent Payment Placeh Prvt | 0.00% |
139 | n/a | Korro Bio Inc Cvr | 0.00% |
140 | n/a | Caremax ([Wts/Rts]) | 0.00% |
141 | n/a | NOK - Spendable Cash | 0.00% |
142 | n/a | GBP - Spendable Cash | 0.00% |
143 | n/a | HKD - Spendable Cash | 0.00% |
144 | n/a | AUD - Spendable Cash | 0.00% |
145 | n/a | USD - Spendable Cash | -0.03% |
As of Mar 31, 2025